On Tuesday, Shares of Alcoa Inc (NYSE:AA), subtract -11.42% and closed at $27.91 in the last trading session. The last trading range of the stock ranges between $27.89 and $29.73. The company’s Market capitalization is $12.29 Billion with the total Outstanding Shares of 438.46 million. During the 52-week trading session the minimum price at which share price traded, registered at $18.42 and reached to max level of $34.50. Lightweight metals leader Alcoa (AA) recently stated third quarter 2016 results. In spite of near-term market challenges, Arconic segments stated combined year-over-year profit growth, and Alcoa Corporation segments, Alumina and Primary Metals, maintained profitability sequentially despite continued low alumina and aluminum pricing by proactively managing costs and capacity. The Company’s separation is planned to become effective before the opening of the market on November 1, 2016.
”Alcoa steered steady and showed resilience in spite of near-term market challenges,” said Klaus Kleinfeld, Alcoa Chairman and Chief Executive Officer. “Profits grew in the combined Arconic segments, and Alcoa Corporation segments managed successfully to stay profitable in a low pricing environment. Productivity across the portfolio was exceptional, and paired with non-essential asset sales, further strengthened our cash position. Arconic’s results underline its strong position in higher margin markets where innovation, technology, process skills and cost focus pay off even under demanding circumstances, whereas Alcoa Corporation proved to be successful in spite of challenging market conditions. The strength of both future companies is the result of our multi-year strategy and allows us to launch two strong, independent entities.”
Medtronic PLC (NYSE:MDT), dropped -3.45% and closed at $83.20 in the last trading session. The last trading range of the stock ranges between $82.27 and $85.99. The company’s Market capitalization is $114.99 Billion with the total Outstanding Shares of 1.38 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $71.03 and reached to max level of $89.27. Medtronic plc (MDT) recently declared positive clinical data for its investigational Avalus(TM) pericardial aortic surgical valve, intended for the treatment of aortic valve disease. Presented at the 30th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting for the first time, results from the PERIGON (PERIcardial SurGical AOrtic Valve ReplacemeNt) Pivotal Trial showed low rates of adverse valve-related events, high survival and improved hemodynamic performance at one year.
One of the leading, most comprehensive and modern data sets of surgical aortic valve replacement (SAVR) patients, the PERIGON Pivotal Trial is a single arm, non-randomized, prospective study of about 1,300 patients from 40 clinical sites across Europe, Canada, Japan and the United States. In the cohort presented at EACTS, outcomes of 270 patients were analyzed at the one-year endpoint. The vast majority (91 percent) of patients were at low mortality risk for open heart surgery (STS<=4 percent), with the remaining 8 percent at intermediate risk (STS=4 to 8 percent) and <1 percent at high risk (STS>=8 percent). At one year, all patients showed low rates of all-cause mortality (3.6 percent) and cardiac death (1.1 percent).